Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

Eosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal‐limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)‐ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA.

[1]  X. Solanich,et al.  Comparison of the Birmingham Vasculitis Activity Score and the Five‐Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry) , 2020, Arthritis care & research.

[2]  Y. Shoenfeld,et al.  International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. , 2020, American journal of respiratory and critical care medicine.

[3]  D. Jayne,et al.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.

[4]  E. Lee,et al.  Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids , 2017, Annals of the rheumatic diseases.

[5]  A. Vaglio,et al.  Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.

[6]  R. Voll,et al.  Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. , 2017, The journal of allergy and clinical immunology. In practice.

[7]  S. Andrulli,et al.  Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial , 2017, PloS one.

[8]  Yong-Beom Park,et al.  Five factor score of more than 1 is associated with relapse during the first 2 year‐follow up in patients with eosinophilic granulomatosis with polyangiitis , 2017, International journal of rheumatic diseases.

[9]  G. Baron,et al.  Adding Azathioprine to Remission‐Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors , 2017, Arthritis & rheumatology.

[10]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[11]  C. Giannattasio,et al.  Comprehensive evaluation of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac magnetic resonance. , 2017, European journal of internal medicine.

[12]  K. Roszkowski-Śliż,et al.  "The significance of cardiac magnetic resonance imaging in detection and monitoring of the treatment efficacy of heart involvement in eosinophilic granulomatosis with polyangiitis patients". , 2016, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[13]  E. Jeon,et al.  Detecting cardiac involvement with magnetic resonance in patients with active eosinophilic granulomatosis with polyangiitis , 2016, The International Journal of Cardiovascular Imaging.

[14]  P. Merkel,et al.  Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.

[15]  S. Heymans,et al.  Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. , 2015, International journal of cardiology.

[16]  E. Ammirati,et al.  [Cardiac involvement in Churg-Strauss syndrome]. , 2015, Giornale italiano di cardiologia.

[17]  O. Vignaux,et al.  Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. , 2015, Autoimmunity reviews.

[18]  P. Ravaud,et al.  Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy , 2015, Arthritis & rheumatology.

[19]  G. Kolovou,et al.  Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance. , 2013, Inflammation & allergy drug targets.

[20]  L. Mouthon,et al.  Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. , 2013, Journal of autoimmunity.

[21]  F. Moosig,et al.  A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients , 2012, Annals of the rheumatic diseases.

[22]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[23]  L. Mastalerz,et al.  Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[24]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[25]  D. Scott,et al.  Epidemiology of ANCA-associated vasculitis. , 2010, Rheumatic diseases clinics of North America.

[26]  W. Kaiser,et al.  Cardiac Involvement in Churg-Strauss Syndrome: Impact of Endomyocarditis , 2009, Medicine.

[27]  H. Gouya,et al.  Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. , 2009, Clinical and experimental rheumatology.

[28]  J. Schulz-Menger,et al.  Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. , 2008, Journal of cardiac failure.

[29]  J. Coste,et al.  The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case–crossover study , 2008, Thorax.

[30]  C. Ribi,et al.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. , 2008, Arthritis and rheumatism.

[31]  A. Buist,et al.  Asthma drug use and the development of Churg–Strauss syndrome (CSS) , 2007, Pharmacoepidemiology and drug safety.

[32]  L. Mouthon,et al.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. , 2007, Arthritis and rheumatism.

[33]  L. Mouthon,et al.  Antineutrophil Cytoplasmic Antibodies and the ChurgStrauss Syndrome , 2005, Annals of Internal Medicine.

[34]  Laura Pavone,et al.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.

[35]  L. Mouthon,et al.  Deaths Occurring During the First Year After Treatment Onset for Polyarteritis Nodosa, Microscopic Polyangiitis, and Churg-Strauss Syndrome: A Retrospective Analysis of Causes and Factors Predictive of Mortality Based on 595 Patients , 2005, Medicine.

[36]  K. De Groot,et al.  Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. , 2004, Clinical and experimental rheumatology.

[37]  A. Gibofsky.  American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[38]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[39]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[40]  G. Hughes,et al.  Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg‐Strauss Syndrome , 1984, Medicine.

[41]  G. Hughes,et al.  Systemic vasculitis with asthma and eosinophilia , 1984 .